Sharpe KP, Berkowitz R, Tyndall WA, et al. - In view of phase 3 randomized multicenter, double-blind, placebo-controlled trial demonstrating the efficacy of meloxicam intravenous (IV) in reducing opioid consumption among adults with moderate-to-severe pain following major elective surgery with a safety profile similar to placebo, researchers conducted this post hoc subgroup analysis investigating the safety and efficacy of meloxicam in reducing opioid consumption among orthopedic surgery individuals. Meloxicam IV 30 mg or IV-administered placebo was provided to 379 individuals every 24 hrs for ≤ 7 doses. The number and frequency of AEs were not significantly different between patients receiving meloxicam IV vs placebo following orthopedic surgery. The meloxicam IV group vs placebo had reduced opioid consumption.